How should the recombinant zoster vaccine (Shingrix) be administered in adults?

How to Administer Shingrix (Recombinant Zoster Vaccine)

Administer Shingrix as two 0.5 mL intramuscular injections into the deltoid muscle, with the second dose given 2-6 months after the first dose (or 1-2 months apart for immunocompromised individuals). 1

Reconstitution and Preparation

Shingrix requires reconstitution before administration:

1. Withdraw the entire contents of the adjuvant suspension vial (liquid) using a sterile needle and syringe
2. Transfer the liquid slowly into the lyophilized antigen vial (powder)
3. Gently swirl until the powder is completely dissolved—do not shake vigorously
4. Inspect the reconstituted vaccine: it should appear opalescent, colorless to pale brownish. Discard if you see particulate matter or discoloration
5. Withdraw 0.5 mL from the reconstituted vaccine vial 1

Administration Technique

• Route: Intramuscular injection only
• Site: Deltoid region of the upper arm (preferred site)
• Timing after reconstitution: Administer immediately OR refrigerate at 2-8°C (36-46°F) and use within 6 hours. Discard if not used within 6 hours
• Use separate sterile needle and syringe for each patient 1

Dosing Schedule

Standard Schedule (Immunocompetent Adults ≥50 years)

• Dose 1: Month 0
• Dose 2: 2-6 months after first dose 1, 2

Accelerated Schedule (Immunocompromised Adults ≥18 years)

• Dose 1: Month 0
• Dose 2: 1-2 months after first dose (for those who would benefit from shorter vaccination schedule) 1, 3

Important timing consideration: When possible, administer the first dose at least 14 days before starting immunosuppressive therapy 4

Key Clinical Pearls

The FDA-approved label 1 takes precedence over older guideline recommendations. While older ACIP guidelines 5, 6, 7, 8 recommended single-dose live zoster vaccine (Zostavax) starting at age 60, current practice strongly favors the 2-dose recombinant vaccine (Shingrix) starting at age 50 9, 10, 11. The recombinant vaccine demonstrates superior efficacy (96% vs 70%) and can be safely used in immunocompromised patients, unlike the live vaccine 9.

Common Pitfalls to Avoid

• Do not shake vigorously during reconstitution—this can damage the vaccine components
• Do not use beyond 6 hours after reconstitution, even if refrigerated
• Do not administer subcutaneously—this is an intramuscular vaccine only
• Do not skip the second dose—real-world effectiveness drops from 70% with 2 doses to only 57% with 1 dose 12
• Do not delay unnecessarily if the second dose interval exceeds 6 months—studies show effectiveness is maintained even with delayed second doses beyond 180 days 12

Special Populations

Immunocompromised patients (including those with HIV, on immunosuppressive therapy, transplant recipients, or with autoimmune conditions): Use the accelerated 1-2 month schedule between doses. Vaccine effectiveness remains clinically meaningful at 64% in this population 3, 13, 14, 15.

Pregnancy: Consider delaying RZV until after pregnancy if otherwise indicated, though no specific harm has been documented 11, 1.

Previous herpes zoster: Vaccinate regardless of prior shingles history 1, 2.

Previous live zoster vaccine (Zostavax): Administer RZV at least 2 months after ZVL 10, 2.